Login to Your Account



La Jolla's Stock Tumbles After Failure Of Phase III Lupus Drug

By Brady Huggett


Wednesday, February 19, 2003
An anticipated Phase III trial of Riquent in lupus, meant to confirm data trends seen in a Phase II/III trial, brought about a similar result - good data trends but a missed primary endpoint, sending La Jolla Pharmaceutical Co.'s stock down 72.5 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription